Executive Intelligence

Andrew Hopkins

Founder

Andrew Hopkins is listed as a founder of Exscientia based in United Kingdom on Brel Digital’s verified company intelligence record.

Company Intelligence Official Website
In this profile

Quick Facts

  • Role Founder
  • Company Exscientia
  • Country United Kingdom
  • Industry AI in Healthcare
  • Founded 2012
  • Known For Exscientia's acquisition by Recursion is a landmark consolidation event in AI drug discovery — combining precision…
  • Status Acquired
  • Last Reviewed Jul 2026

Executive Summary

Andrew Hopkins appears in Brel Digital’s verified company_founders attribution for Exscientia based in United Kingdom in the Healthcare sector. This profile records that founder relationship using sources already on file for the company. Personal biography details that are not evidenced in those sources are omitted. Company context (from the verified Exscientia profile): Oxford AI drug design pioneer acquired by Recursion in November 2024; now a wholly owned subsidiary Why the company matters (verified company field): Exscientia's acquisition by Recursion is a landmark consolidation event in AI drug discovery — combining precision chemistry automation with Recursion's phenotypic screening platform under one Nasdaq-listed parent. Official company website on file: https://www.exscientia.com. Readers should consult that site and the Sources section for primary evidence. Brel Digital does not invent prior roles, education, funding history, or awards for founder profiles. Where additional verified public leadership pages become available, this profile should be deepened in a subsequent editorial review.

Career Timeline

Verified company milestones linked to this executive’s organization.

  1. 2012 Company founded

    Exscientia was founded in 2012 per the company profile source on file.

    Source
  2. 2012 Development

    2012: Exscientia founded in Oxford area by Andrew Hopkins as University of Dundee spinout.

    Source
  3. 2024 Development

    November 20, 2024: Recursion completed combination with Exscientia; Exscientia became wholly owned subsidiary and delisted from Nasdaq.

    Source
  4. Development

    exscientia.com redirects to Recursion at review time.

    Source
  5. Company status

    Documented status on Brel profile: Acquired.

    Source

Connected Company

Connected Products

Connected Reports

Connected Insights

Industry Intelligence

AI in Healthcare Open industry

Andrew Hopkins appears in Brel Digital’s verified company_founders attribution for Exscientia based in United Kingdom in the Healthcare sector. This profile records that founder relationship using sources already on file for the company. Personal biography details that are not evidenced in those sources are omitted.

Company context (from the verified Exscientia profile): Oxford AI drug design pioneer acquired by Recursion in November 2024; now a wholly owned subsidiary

Why the company matters (verified company field): Exscientia's acquisition by Recursion is a landmark consolidation event in AI drug discovery — combining precision chemistry automation with Recursion's phenotypic screening platform under one Nasdaq-listed parent.

Official company website on file: https://www.exscientia.com. Readers should consult that site and the Sources section for primary evidence.

Brel Digital does not invent prior roles, education, funding history, or awards for founder profiles. Where additional verified public leadership pages become available, this profile should be deepened in a subsequent editorial review.

Sources and references

This article draws on publicly available company information, official websites, filings, interviews, announcements, and other cited sources. Information may change over time.

Request a correction if you represent this company or believe information is inaccurate.

The AI Brief

Founder and company intelligence, weekly.

Subscribe